JAK2基因V617F突变对骨髓纤维化异基因造血干细胞移植（HSCT）后结局无影响。 - Suppr

Suppr

超能文献

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

作者信息

Ditschkowski Markus, Elmaagacli Ahmet H, Trenschel Rudolf, Steckel Nina K, Koldehoff Michael, Beelen Dietrich W

出版信息

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. doi: 10.1016/j.bbmt.2006.07.010.

DOI:10.1016/j.bbmt.2006.07.010

PMID:17162218

Abstract

摘要

相似文献

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. doi: 10.1016/j.bbmt.2006.07.010.

The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.

Clin Adv Hematol Oncol. 2009 May;7(5):334-42.

A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.

Hematol Oncol. 2006 Dec;24(4):227-33. doi: 10.1002/hon.800.

Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.

Am J Hematol. 2007 Jan;82(1):80-2. doi: 10.1002/ajh.20721.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Orv Hetil. 2006 Nov 12;147(45):2175-9.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Eur J Haematol. 2007 Dec;79(6):508-15. doi: 10.1111/j.1600-0609.2007.00960.x. Epub 2007 Oct 23.

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.

Am J Hematol. 2007 May;82(5):400-2. doi: 10.1002/ajh.20832.

Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.

Blood Cells Mol Dis. 2012;49(3-4):170-6. doi: 10.1016/j.bcmd.2012.06.004. Epub 2012 Jul 19.

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.

Blood. 2006 Mar 1;107(5):2098-100. doi: 10.1182/blood-2005-08-3395. Epub 2005 Nov 17.

A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis.

Leukemia. 2007 Jun;21(6):1331-2. doi: 10.1038/sj.leu.2404649. Epub 2007 Mar 15.

引用本文的文献

JAK2 V617F mutation and associated chromosomal alterations in primary and secondary myelofibrosis and post-HCT outcomes.

Blood Adv. 2023 Dec 26;7(24):7506-7515. doi: 10.1182/bloodadvances.2023010882.

Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021.

Front Immunol. 2021 May 4;12:637512. doi: 10.3389/fimmu.2021.637512. eCollection 2021.

Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.

Ther Adv Hematol. 2020 Feb 13;11:2040620720906002. doi: 10.1177/2040620720906002. eCollection 2020.

State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019.

Haematologica. 2019 Apr;104(4):659-668. doi: 10.3324/haematol.2018.206151. Epub 2019 Mar 14.

Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

Leuk Suppl. 2012 May;1(Suppl 1):S2-7. doi: 10.1038/leusup.2012.2. Epub 2012 May 9.

Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Blood. 2012 Aug 16;120(7):1367-79. doi: 10.1182/blood-2012-05-399048. Epub 2012 Jun 14.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Haematologica. 2012 Oct;97(10):1574-81. doi: 10.3324/haematol.2011.061168. Epub 2012 Apr 4.

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

Blood. 2012 Mar 15;119(11):2657-64. doi: 10.1182/blood-2011-08-372904. Epub 2012 Jan 10.

Reduced-intensity conditioning followed by allogeneic hematopoietic stem cell transplantation in myelofibrosis.

Curr Hematol Malig Rep. 2010 Apr;5(2):53-61. doi: 10.1007/s11899-010-0044-z.

Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Biol Blood Marrow Transplant. 2010 Feb;16(2):281-6. doi: 10.1016/j.bbmt.2009.09.020. Epub 2009 Sep 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验